Zobrazeno 1 - 10
of 193
pro vyhledávání: '"Seiya Yamayoshi"'
Autor:
Satoshi Fukuyama, Jason E. Shoemaker, Dongming Zhao, Noriko Nagajima, Yuriko Tomita, Tadashi Maemura, Tiago Jose da Silva Lopes, Tokiko Watanabe, Seiya Yamayoshi, Hideki Hasegawa, Yoshihiro Kawaoka
Publikováno v:
npj Viruses, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Influenza A(H7N9) virus showed high pathogenicity in humans when it emerged in 2013. Cigarette smoke (CS) causes pulmonary diseases including bronchitis, emphysema, and lung cancer. Although habitual smoking is thought to increase the risk o
Externí odkaz:
https://doaj.org/article/d693870eecb54a2c9d517cf4699b35ae
Autor:
Peter J. Halfmann, Kiyoko Iwatsuki-Horimoto, Makoto Kuroda, Yuichiro Hirata, Seiya Yamayoshi, Shun Iida, Ryuta Uraki, Mutsumi Ito, Hiroshi Ueki, Yuri Furusawa, Yuko Sakai-Tagawa, Maki Kiso, Tammy Armbrust, Sam Spyra, Ken Maeda, Zhongde Wang, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-7 (2024)
Abstract During the Omicron wave, previous variants such as BA.2, BA.4, and BA.5 were replaced by newer variants with additional mutations in the spike protein. These variants, BA.4.6, BQ.1.1, and XBB, have spread in different countries with differen
Externí odkaz:
https://doaj.org/article/7b6dc5728b27475ca7af06992e1a8732
Autor:
Ryuta Uraki, Masaki Imai, Mutsumi Ito, Seiya Yamayoshi, Maki Kiso, Nao Jounai, Kazuki Miyaji, Kiyoko Iwatsuki-Horimoto, Fumihiko Takeshita, Yoshihiro Kawaoka
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Here, we assessed the efficacy of a lipid nanoparticle-based mRNA vaccine candidate encoding the receptor-binding domain (LNP-mRNA-RBD) in mice. Mice immunized with LNP-mRNA-RBD based on the ancestral strain (ancestral-type LNP-mRNA-RBD) sho
Externí odkaz:
https://doaj.org/article/427759ac641440db840a7f2931caa239
Autor:
Aya Ishizaka, Michiko Koga, Taketoshi Mizutani, Seiya Yamayoshi, Kiyoko Iwatsuki-Horimoto, Eisuke Adachi, Yutaka Suzuki, Yoshihiro Kawaoka, Hiroshi Yotsuyanagi
Publikováno v:
BMC Microbiology, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background People living with HIV (PLWH) with chronic inflammation may have an increasing risk for coronavirus disease 2019 (COVID-19) severity; however, the impact of their gut microbiota on COVID-19 is not fully elucidated. Here, we analyz
Externí odkaz:
https://doaj.org/article/77d1edc4399a421982cd88866ec3457a
Autor:
Aya Ishizaka, Michiko Koga, Taketoshi Mizutani, Ryuta Uraki, Seiya Yamayoshi, Kiyoko Iwatsuki-Horimoto, Shinya Yamamoto, Masaki Imai, Takeya Tsutsumi, Yutaka Suzuki, Yoshihiro Kawaoka, Hiroshi Yotsuyanagi
Publikováno v:
Virology Journal, Vol 20, Iss 1, Pp 1-12 (2023)
Abstract Background The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce sec
Externí odkaz:
https://doaj.org/article/6f1b2a1c7f034610aa818248bc6ecbb1
Autor:
Maki Kiso, Seiya Yamayoshi, Shun Iida, Yuri Furusawa, Yuichiro Hirata, Ryuta Uraki, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
Abstract Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to most monoclonal
Externí odkaz:
https://doaj.org/article/35fa4f4c459e449fb6a5f48e729cbbac
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
Abstract Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is clinically useful against infection with SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to many mo
Externí odkaz:
https://doaj.org/article/ab06f1a03d3e47acac3756eb1faf1106
Autor:
Ryuta Uraki, Maki Kiso, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Mutsumi Ito, Shiho Chiba, Yuko Sakai-Tagawa, Masaki Imai, Yukie Kashima, Michiko Koga, Noriko Fuwa, Nobumasa Okumura, Masayuki Hojo, Noriko Iwamoto, Hideaki Kato, Hideaki Nakajima, Norio Ohmagari, Hiroshi Yotsuyanagi, Yutaka Suzuki, Yoshihiro Kawaoka
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113580- (2023)
Summary: EG.5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide. However, the pathogenicity, transmissibility, and immune evasion properties of
Externí odkaz:
https://doaj.org/article/3359de53c5544266aee6bf7bded1cffe
Autor:
Seiya Yamayoshi, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Atsuhiro Yasuhara, Moe Okuda, Taiki Hamabata, Jurika Murakami, Calvin Duong, Tsukasa Yamamoto, Yudai Kuroda, Ken Maeda, Yoshihiro Kawaoka
Publikováno v:
One Health, Vol 17, Iss , Pp 100588- (2023)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to circulate in humans since its emergence in 2019. While infection in humans continues, numerous spillover events to at least 32 animal species, including companion and zoo a
Externí odkaz:
https://doaj.org/article/31f2abccbea2450c8140051f92ab1d78
Autor:
Ryuta Uraki, Mutsumi Ito, Maki Kiso, Seiya Yamayoshi, Kiyoko Iwatsuki-Horimoto, Yuko Sakai-Tagawa, Masaki Imai, Michiko Koga, Shinya Yamamoto, Eisuke Adachi, Makoto Saito, Takeya Tsutsumi, Amato Otani, Shuetsu Fukushi, Shinji Watanabe, Tadaki Suzuki, Tetsuhiro Kikuchi, Hiroshi Yotsuyanagi, Ken Maeda, Yoshihiro Kawaoka
Publikováno v:
iScience, Vol 26, Iss 11, Pp 108147- (2023)
Summary: The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAb
Externí odkaz:
https://doaj.org/article/bcc9e8dce069400aa6ad9a843503c254